therapeuticЮжно-Российский журнал терапевтической практикиSouth Russian Journal of Therapeutic Practice2712-81563033-8344РостГМУ10.21886/2712-8156-2023-4-3-27-35therapeutic-395Research ArticleОБЗОРЫREVIEWSФармакологические аспекты каннабиноидовPharmacological aspects of cannabinoidshttps://orcid.org/0000-0003-4625-6186СафроненкоА. В.SafronenkoA. V.

Сафроненко Андрей Владимирович - доктор медицинских наук, доцент, заведующий кафедрой фармакологии и клинической фармакологии.

Ростов-на-Дону

Safronenko Andrey V. - Dr. Sci. (Med.), Docent, Head of Department of Pharmacology and Clinical Pharmacology.

Rostov-on-Don

andrejsaf@mail.ruhttps://orcid.org/0009-0009-5653-6748СаенкоН. Ю.SaenkoN. Yu.

Саенко Наталья Юрьевна - кандидат медицинских наук, доцент кафедры фармакологии и клинической фармакологии.

Ростов-на-Дону

Saenko Natalya Yu. -- Cand. Sci. (Med.), Associate Professor of the Department of Pharmacology and Clinical Pharmacology.

Rostov-on-Don

sayenko.60@mail.ruhttps://orcid.org/0009-0005-0027-0582ЗемляковаВ. П.ZemliakovaV. P.

Землякова Владислава Павловна - студентка 3 курса лечебно-профилактического факультета.

Ростов-на-Дону

Zemliakova Vladislava P. - 3rd year student, Faculty of General Medicine.

Rostov-on-Don

vladazemlyackova@gmail.comhttps://orcid.org/0009-0007-3341-1323КварацхелияС. К.KvaratskheliiaS. K.

Кварацхелия Саломе Кобаевна - студентка 3 курса лечебно-профилактического факультета.

Ростов-на-Дону

Kvaratskheliia Salome K. - 3rd year student, Faculty of General Medicine.

Rostov-on-Don

salomeya02@mail.ruhttps://orcid.org/0009-0002-9589-1506ДольниковаМ. В.DolnikovaM. V.

Дольникова Мария Владиславовна - студентка 3 курса лечебно-профилактического факультета.

Ростов-на-Дону

Dolnikova Mariia V. - 3rd year student, Faculty of General Medicine.

Rostov-on-Don

super.mashad2003@ya.ruФГБОУ ВО «Ростовский государственный медицинский университет» Минздрава РоссииРоссияRostov State Medical UniversityRussian Federation202325092023432735Copyright © Сафроненко А.В., Саенко Н.Ю., Землякова В.П., Кварацхелия С.К., Дольникова М.В., 20232023Сафроненко А.В., Саенко Н.Ю., Землякова В.П., Кварацхелия С.К., Дольникова М.В.Safronenko A.V., Saenko N.Y., Zemliakova V.P., Kvaratskheliia S.K., Dolnikova M.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.therapeutic-j.ru/jour/article/view/395

В настоящем обзоре представлена имеющаяся информация за последнее время о свойствах эндогенных и экзогенных каннабиноидов, возможных механизмах их действия и эффектах. В работе отражен зарубежный опыт использования препаратов (каннабиноидов) по рекомендованным показаниям, а также возможное перспективное действие для расширения их клинического применения.

This review presents recently available information on the properties of endogenous and exogenous cannabinoids, their possible mechanisms of action and effects. The article reflects foreign experience in the use of cannabinoid preparations for the recommended indications, as well as possible promising effects for the expansion of their clinical use.

эндоканнабиноидыэндоканнабиноидные рецепторыканнабидиолтетрагидроканнабинолобзорendocannabinoidsendocannabinoid receptorscannabidioltetrahydrocannabinolreviewИсследование не имело спонсорской поддержкиReferencesPantoja-Ruiz C, Restrepo-Jimenez P, Castañeda-Cardona C, Ferreirós A, Rosselli D. Cannabis and pain: a scoping review. Braz J Anesthesiol. 2022;72(1):142-151. DOI: 10.1016/j.bjane.2021.06.018Pantoja-Ruiz C, Restrepo-Jimenez P, Castañeda-Cardona C, Ferreirós A, Rosselli D. Cannabis and pain: a scoping review. Braz J Anesthesiol. 2022;72(1):142-151. DOI:10.1016/j.bjane.2021.06.018Crocq MA. History of cannabis and the endocannabinoid system. Dialogues Clin Neurosci. 2020;22(3):223-228. DOI: 10.31887/DCNS.2020.22.3/mcrocqCrocq MA. History of cannabis and the endocannabinoid system. Dialogues Clin Neurosci. 2020;22(3):223-228. DOI:10.31887/DCNS.2020.22.3/mcrocqAdams R, Hunt M, Clark JH. Structure of Cannabidiol, a Product Isolated from the Marihuana Extract of Minnesota Wild Hemp. J. Am. Chem. Soc. 1940;62(1):196-200. DOI: 10.1021/ja01858a058Adams R, Hunt M, Clark JH. Structure of Cannabidiol, a Product Isolated from the Marihuana Extract of Minnesota Wild Hemp. J. Am. Chem. Soc. 1940;62(1):196-200. DOI: 10.1021/ja01858a058Gaoni Y, Mechoulam R. Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish. J. Am. Chem. Soc. 1964;86(8):1646-1647. DOI: 10.1021/ja01062a046Gaoni Y, Mechoulam R. Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish. J. Am. Chem. Soc. 1964;86(8):1646-1647. DOI: 10.1021/ja01062a046Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 1988;34(5):605-613. PMID: 2848184Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 1988;34(5):605-613. PMID: 2848184Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258(5090):1946-1949. DOI: 10.1126/science.1470919Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258(5090):1946-1949. DOI:10.1126/science.1470919Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365(6441):61-65. DOI: 10.1038/365061a0Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365(6441):61-65. DOI:10.1038/365061a0Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun. 1995;215(1):89-97. DOI: 10.1006/bbrc.1995.2437Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun. 1995;215(1):89-97. DOI:10.1006/bbrc.1995.2437Ahmad A. Endocannabinoid system: An untold story in hypertensive nephropathy. Electron J Gen Med. 2023;20(3):em481. DOI: 10.29333/ejgm/13055Ahmad A. Endocannabinoid system: An untold story in hypertensive nephropathy. Electron J Gen Med. 2023;20(3):em481. DOI:10.29333/ejgm/13055Amin MR, Ali DW. Pharmacology of Medical Cannabis. Adv Exp Med Biol. 2019;1162:151-165. DOI: 10.1007/978-3-030-21737-2_8Amin MR, Ali DW. Pharmacology of Medical Cannabis. Adv Exp Med Biol. 2019;1162:151-165. DOI:10.1007/978-3-030-21737-2_8Morris G, Walder K, Kloiber S, Amminger P, Berk M, Bortolasci CC, et al. The endocannabinoidome in neuropsychiatry: Opportunities and potential risks. Pharmacol Res. 2021;170:105729. DOI: 10.1016/j.phrs.2021.105729Morris G, Walder K, Kloiber S, Amminger P, Berk M, Bortolasci CC, et al. The endocannabinoidome in neuropsychiatry: Opportunities and potential risks. Pharmacol Res. 2021;170:105729. DOI:10.1016/j.phrs.2021.105729Lu HC, Mackie K. Review of the Endocannabinoid System. Biol Psychiatry Cogn Neurosci Neuroimaging. 2021;6(6):607-615. DOI: 10.1016/j.bpsc.2020.07.016Lu HC, Mackie K. Review of the Endocannabinoid System. Biol Psychiatry Cogn Neurosci Neuroimaging. 2021;6(6):607-615. DOI:10.1016/j.bpsc.2020.07.016Palmisano M, Gargano A, Olabiyi BF, Lutz B, Bilkei-Gorzo A. Hippocampal Deletion of CB1 Receptor Impairs Social Memory and Leads to Age-Related Changes in the Hippocampus of Adult Mice. Int J Mol Sci. 2022;24(1):26. DOI: 10.3390/ijms24010026Palmisano M, Gargano A, Olabiyi BF, Lutz B, Bilkei-Gorzo A. Hippocampal Deletion of CB1 Receptor Impairs Social Memory and Leads to Age-Related Changes in the Hippocampus of Adult Mice. Int J Mol Sci. 2022;24(1):26. DOI:10.3390/ijms24010026Meyer JS, Farrar AM. Marijuana and the Cannabinoids. In: Biezonski D, Yates JR, editors. Psychopharmacology. Drugs, the brain, behavior. 4th ed. Sunderland, Massachusetts, USA: Oxford University Press; 2023. p. 445-482.Meyer JS, Farrar AM. Marijuana and the Cannabinoids. In: Biezonski D, Yates JR, editors. Psychopharmacology. Drugs, the brain, behavior. 4th ed. Sunderland, Massachusetts, USA: Oxford University Press; 2023. p. 445-482.Scarante FF, Vila-Verde C, Detoni VL, Ferreira-Junior NC, Guimarães FS, Campos AC. Cannabinoid Modulation of the Stressed Hippocampus. Front Mol Neurosci. 2017;10:411. DOI: 10.3389/fnmol.2017.00411Scarante FF, Vila-Verde C, Detoni VL, Ferreira-Junior NC, Guimarães FS, Campos AC. Cannabinoid Modulation of the Stressed Hippocampus. Front Mol Neurosci. 2017;10:411. DOI:10.3389/fnmol.2017.00411Moore CF, Weerts EM. Cannabinoid tetrad effects of oral Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in male and female rats: sex, dose-effects and time course evaluations. Psychopharmacology (Berl). 2022;239(5):1397-1408. DOI: 10.1007/s00213-021-05995-5Moore CF, Weerts EM. Cannabinoid tetrad effects of oral Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in male and female rats: sex, dose-effects and time course evaluations. Psychopharmacology (Berl). 2022;239(5):1397-1408. DOI:10.1007/s00213-021-05995-5Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol. 2018;84(11):2477-2482. DOI: 10.1111/bcp.13710Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol. 2018;84(11):2477-2482. DOI:10.1111/bcp.13710Fraguas-Sánchez AI, Torres-Suárez AI. Medical Use of Cannabinoids. Drugs. 2018;78(16):1665-1703. DOI: 10.1007/s40265-018-0996-1Fraguas-Sánchez AI, Torres-Suárez AI. Medical Use of Cannabinoids. Drugs. 2018;78(16):1665-1703. DOI:10.1007/s40265-018-0996-1Prieto González JM, Vila Silván C. Safety and tolerability of nabiximols oromucosal spray: a review of more than 15 years" accumulated evidence from clinical trials. Expert Rev Neurother. 2021;21(7):755-778. DOI: 10.1080/14737175.2021.1935879Prieto González JM, Vila Silván C. Safety and tolerability of nabiximols oromucosal spray: a review of more than 15 years" accumulated evidence from clinical trials. Expert Rev Neurother. 2021;21(7):755-778. DOI:10.1080/14737175.2021.1935879Abu-Sawwa R, Stehling C. Epidiolex (Cannabidiol) Primer: Frequently Asked Questions for Patients and Caregivers. J Pediatr Pharmacol Ther. 2020;25(1):75-77. DOI: 10.5863/1551-6776-25.1.75Abu-Sawwa R, Stehling C. Epidiolex (Cannabidiol) Primer: Frequently Asked Questions for Patients and Caregivers. J Pediatr Pharmacol Ther. 2020;25(1):75-77. DOI:10.5863/1551-6776-25.1.75Georgieva D, Langley J, Hartkopf K, Hawk L, Margolis A, Struck A, et al. Real-world, long-term evaluation of the tolerability and therapy retention of Epidiolex® (cannabidiol) in patients with refractory epilepsy. Epilepsy Behav. 2023;141:109159. DOI: 10.1016/j.yebeh.2023.109159Georgieva D, Langley J, Hartkopf K, Hawk L, Margolis A, Struck A, et al. Real-world, long-term evaluation of the tolerability and therapy retention of Epidiolex® (cannabidiol) in patients with refractory epilepsy. Epilepsy Behav. 2023;141:109159. DOI:10.1016/j.yebeh.2023.109159Tagen M, Klumpers LE. Review of delta-8-tetrahydrocannabinol (Δ8 -THC): Comparative pharmacology with Δ9 -THC. Br J Pharmacol. 2022;179(15):3915-3933. DOI: 10.1111/bph.15865Tagen M, Klumpers LE. Review of delta-8-tetrahydrocannabinol (Δ8 -THC): Comparative pharmacology with Δ9 -THC. Br J Pharmacol. 2022;179(15):3915-3933. DOI:10.1111/bph.15865Legare CA, Raup-Konsavage WM, Vrana KE. Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals. Pharmacology. 2022;107(3-4):131-149. DOI: 10.1159/000521683Legare CA, Raup-Konsavage WM, Vrana KE. Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals. Pharmacology. 2022;107(3-4):131-149. DOI:10.1159/000521683Badowski ME. A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics. Cancer Chemother Pharmacol. 2017;80(3):441-449. DOI: 10.1007/s00280-017-3387-5Badowski ME. A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics. Cancer Chemother Pharmacol. 2017;80(3):441-449. DOI:10.1007/s00280-017-3387-5Cohen K, Weizman A, Weinstein A. Positive and Negative Effects of Cannabis and Cannabinoids on Health. Clin Pharmacol Ther. 2019;105(5):1139-1147. DOI: 10.1002/cpt.1381Cohen K, Weizman A, Weinstein A. Positive and Negative Effects of Cannabis and Cannabinoids on Health. Clin Pharmacol Ther. 2019;105(5):1139-1147. DOI:10.1002/cpt.1381Rock EM, Parker LA. Constituents of Cannabis Sativa. Adv Exp Med Biol. 2021;1264:1-13. DOI: 10.1007/978-3-030-57369-0_1Rock EM, Parker LA. Constituents of Cannabis Sativa. Adv Exp Med Biol. 2021;1264:1-13. DOI:10.1007/978-3-030-57369-0_1Mlost J, Bryk M, Starowicz K. Cannabidiol for Pain Treatment: Focus on Pharmacology and Mechanism of Action. Int J Mol Sci. 2020;21(22):8870. DOI: 10.3390/ijms21228870Mlost J, Bryk M, Starowicz K. Cannabidiol for Pain Treatment: Focus on Pharmacology and Mechanism of Action. Int J Mol Sci. 2020;21(22):8870. DOI:10.3390/ijms21228870Yu W, Jin G, Zhang J, Wei W. Selective Activation of Cannabinoid Receptor 2 Attenuates Myocardial Infarction via Suppressing NLRP3 Inflammasome. Inflammation. 2019;42(3):904-914. DOI: 10.1007/s10753-018-0945-xYu W, Jin G, Zhang J, Wei W. Selective Activation of Cannabinoid Receptor 2 Attenuates Myocardial Infarction via Suppressing NLRP3 Inflammasome. Inflammation. 2019;42(3):904-914. DOI:10.1007/s10753-018-0945-xWu HM, Kim TH, Kim A, Koo JH, Joo MS, Kim SG. Liver X Receptor α-Induced Cannabinoid Receptor 2 Inhibits Ubiquitin-Specific Peptidase 4 Through miR-27b, Protecting Hepatocytes From TGF-β. Hepatol Commun. 2019;3(10):1373-1387. DOI: 10.1002/hep4.1415Wu HM, Kim TH, Kim A, Koo JH, Joo MS, Kim SG. Liver X Receptor α-Induced Cannabinoid Receptor 2 Inhibits Ubiquitin-Specific Peptidase 4 Through miR-27b, Protecting Hepatocytes From TGF-β. Hepatol Commun. 2019;3(10):1373-1387. DOI:10.1002/hep4.1415Tartakover Matalon S, Ringel Y, Konikoff F, Drucker L, Pery S, Naftali T. Cannabinoid receptor 2 agonist promotes parameters implicated in mucosal healing in patients with inflammatory bowel disease. United European Gastroenterol J. 2020;8(3):271-283. DOI: 10.1177/2050640619889773Tartakover Matalon S, Ringel Y, Konikoff F, Drucker L, Pery S, Naftali T. Cannabinoid receptor 2 agonist promotes parameters implicated in mucosal healing in patients with inflammatory bowel disease. United European Gastroenterol J. 2020;8(3):271-283. DOI:10.1177/2050640619889773Zhu M, Yu B, Bai J, Wang X, Guo X, Liu Y, et al. Cannabinoid Receptor 2 Agonist Prevents Local and Systemic Inflammatory Bone Destruction in Rheumatoid Arthritis. J Bone Miner Res. 2019;34(4):739-751. DOI: 10.1002/jbmr.3637Zhu M, Yu B, Bai J, Wang X, Guo X, Liu Y, et al. Cannabinoid Receptor 2 Agonist Prevents Local and Systemic Inflammatory Bone Destruction in Rheumatoid Arthritis. J Bone Miner Res. 2019;34(4):739-751. DOI:10.1002/jbmr.3637Cabañero D, Ramírez-López A, Drews E, Schmöle A, Otte DM, Wawrzczak-Bargiela A, et al. Protective role of neuronal and lymphoid cannabinoid CB2 receptors in neuropathic pain. Elife. 2020;9:e55582. DOI: 10.7554/eLife.55582Cabañero D, Ramírez-López A, Drews E, Schmöle A, Otte DM, Wawrzczak-Bargiela A, et al. Protective role of neuronal and lymphoid cannabinoid CB2 receptors in neuropathic pain. Elife. 2020;9:e55582. DOI:10.7554/eLife.55582Krzyżewska A, Baranowska-Kuczko M, Mińczuk K, Kozłowska H. Cannabinoids—A New Perspective in Adjuvant Therapy for Pulmonary Hypertension. Int. J. Mol. Sci. 2021;22(18):10048. DOI: 10.3390/ijms221810048Krzyżewska A, Baranowska-Kuczko M, Mińczuk K, Kozłowska H. Cannabinoids—A New Perspective in Adjuvant Therapy for Pulmonary Hypertension. Int. J. Mol. Sci. 2021;22(18):10048. DOI:10.3390/ijms221810048

The authors declare that there are no conflicts of interest present.